Urologic malignancies: advances in the analysis and interpretation of clinical findings

doi:10.2144/fsoa-2020-0210

Editorial

. 2021 Feb 4;7(4):FSO674.

doi: 10.2144/fsoa-2020-0210.

Urologic malignancies: advances in the analysis and interpretation of clinical findings

Affiliations

¹ Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples 80131, Italy.
² Department of Oncology & Hematology, Regional Reference Center for Rare Tumors, AOU Federico II of Naples, Naples 80131, Italy.
³ Division of Urology, European Institute of Oncology-IRCCS, Milan 20122, Italy.
⁴ Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Naples 80055, Italy.
⁵ Department of Urology, Humanitas Clinical & Research Center-IRCCS, Rozzano, Milan 20089, Italy.
⁶ Andrology & Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, Terni 05100, Italy.
⁷ Department of Urology, Ospedale Pederzoli, Peschiera del Garda, Verona 37019, Italy.
⁸ Department of Urology, San Bassiano Hospital, Bassano del Grappa, Vicenza 36061, Italy.
⁹ UOC of Medical Oncology, ASL NA 2 Nord, "S M delle Grazie" Hospital, Pozzuoli, Naples 80078, Italy.
¹⁰ Department of Clinical Medicine & Surgery, University Federico II of Naples, Naples 80131, Italy.

PMID: 33815820
PMCID: PMC8015670
DOI: 10.2144/fsoa-2020-0210

Editorial

Urologic malignancies: advances in the analysis and interpretation of clinical findings

Felice Crocetto et al. Future Sci OA. 2021.

. 2021 Feb 4;7(4):FSO674.

doi: 10.2144/fsoa-2020-0210.

Authors

Affiliations

¹ Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples 80131, Italy.
² Department of Oncology & Hematology, Regional Reference Center for Rare Tumors, AOU Federico II of Naples, Naples 80131, Italy.
³ Division of Urology, European Institute of Oncology-IRCCS, Milan 20122, Italy.
⁴ Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Naples 80055, Italy.
⁵ Department of Urology, Humanitas Clinical & Research Center-IRCCS, Rozzano, Milan 20089, Italy.
⁶ Andrology & Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, Terni 05100, Italy.
⁷ Department of Urology, Ospedale Pederzoli, Peschiera del Garda, Verona 37019, Italy.
⁸ Department of Urology, San Bassiano Hospital, Bassano del Grappa, Vicenza 36061, Italy.
⁹ UOC of Medical Oncology, ASL NA 2 Nord, "S M delle Grazie" Hospital, Pozzuoli, Naples 80078, Italy.
¹⁰ Department of Clinical Medicine & Surgery, University Federico II of Naples, Naples 80131, Italy.

PMID: 33815820
PMCID: PMC8015670
DOI: 10.2144/fsoa-2020-0210

No abstract available

Keywords: biomarkers; immunotherapy; urologic malignancies.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure C Buonerba is a member of the Editorial Board of Future Science OA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Cited by

Assessing muscle invasion in bladder cancer via virtual biopsy: a study on quantitative parameters and classical radiomics features from dual-energy CT imaging.
Hu M, Wei W, Zhang J, Wang S, Tong X, Fan Y, Cheng Q, Liu Y, Li J, Liu L. Hu M, et al. BMC Med Imaging. 2024 Sep 16;24(1):245. doi: 10.1186/s12880-024-01427-w. BMC Med Imaging. 2024. PMID: 39285354 Free PMC article.
Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review.
Long G, Ma S, Shi R, Sun Y, Hu Z, Chen K. Long G, et al. Cancers (Basel). 2022 Feb 9;14(4):866. doi: 10.3390/cancers14040866. Cancers (Basel). 2022. PMID: 35205613 Free PMC article. Review.
An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines.
Zaccagnino A, Vynnytska-Myronovska B, Stöckle M, Junker K. Zaccagnino A, et al. Int J Mol Sci. 2023 Mar 15;24(6):5648. doi: 10.3390/ijms24065648. Int J Mol Sci. 2023. PMID: 36982721 Free PMC article.
Examining the causal association between psoriasis and bladder cancer: A two-sample Mendelian randomization analysis.
Du L, Wang B, Wen J, Zhang N. Du L, et al. Skin Res Technol. 2024 Apr;30(4):e13663. doi: 10.1111/srt.13663. Skin Res Technol. 2024. PMID: 38533746 Free PMC article.
Exploring the Multifactorial Landscape of Penile Cancer: A Comprehensive Analysis of Risk Factors.
Amicuzi U, Grillo M, Stizzo M, Olivetta M, Tammaro S, Napolitano L, Reccia P, De Luca L, Rubinacci A, Della Rosa G, Lecce A, Coppola P, Papi S, Trama F, Romano L, Sciorio C, Spirito L, Crocetto F, Manfredi C, Del Giudice F, Ferro M, Rocco B, Tataru OS, Balsamo R, Lucarelli G, Del Biondo D, Barone B. Amicuzi U, et al. Diagnostics (Basel). 2024 Aug 16;14(16):1790. doi: 10.3390/diagnostics14161790. Diagnostics (Basel). 2024. PMID: 39202278 Free PMC article. Review.

See all "Cited by" articles

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J. Clin. 70, 7–30 (2020). - PubMed
1. Rescigno P, Buonerba C, Bellmunt J et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets 13, 1676–1686 (2012). - PubMed
1. Pagliuca M, Buonerba C, Fizazi K et al. The evolving systemic treatment landscape for patients with advanced prostate cancer. Drugs 79, 381–400 (2019). - PubMed
1. Ferro M, Lucarelli G, Crocetto F et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. Crit. Rev. Oncol. Hematol. 103198. (2020) (Epub ahead of print). - PubMed
1. Buonerba C, Ferro M, Dolce P et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol . 151, 102992 (2020). - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J. Clin. 70, 7–30 (2020). - PubMed

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J. Clin. 70, 7–30 (2020). - PubMed

[3] Rescigno P, Buonerba C, Bellmunt J et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets 13, 1676–1686 (2012). - PubMed

[4] Rescigno P, Buonerba C, Bellmunt J et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets 13, 1676–1686 (2012). - PubMed

[5] Pagliuca M, Buonerba C, Fizazi K et al. The evolving systemic treatment landscape for patients with advanced prostate cancer. Drugs 79, 381–400 (2019). - PubMed

[6] Pagliuca M, Buonerba C, Fizazi K et al. The evolving systemic treatment landscape for patients with advanced prostate cancer. Drugs 79, 381–400 (2019). - PubMed

[7] Ferro M, Lucarelli G, Crocetto F et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. Crit. Rev. Oncol. Hematol. 103198. (2020) (Epub ahead of print). - PubMed

[8] Ferro M, Lucarelli G, Crocetto F et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. Crit. Rev. Oncol. Hematol. 103198. (2020) (Epub ahead of print). - PubMed

[9] Buonerba C, Ferro M, Dolce P et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol . 151, 102992 (2020). - PubMed

[10] Buonerba C, Ferro M, Dolce P et al. Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol . 151, 102992 (2020). - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Urologic malignancies: advances in the analysis and interpretation of clinical findings

Affiliations

Urologic malignancies: advances in the analysis and interpretation of clinical findings

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources